Telmisartan and Rosuvastatin Tablets 40/5 mg
Telmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
IlYang Biopharm Co., Ltd.
MFDS item code 202101823 · Approved 2021.02.24
This product's status changed to Expired on 2026.02.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of arteriosclerosis progression
This medication is used for patients who require both Telmisartan and Rosuvastatin. Telmisartan helps with the treatment of essential hypertension and reduces the risk of cardiovascular diseases. It particularly lowers the risk of myocardial infarction, stroke, and cardiovascular-related mortality in high-risk patients for whom ACE inhibitors are difficult to use. Rosuvastatin Calcium is primarily used as an adjunct to diet in patients with hypercholesterolemia and dyslipidemia and delays the progression of atherosclerosis. Additionally, it is effective in reducing the risks of stroke, myocardial infarction, and vascular reintervention in patients with a high risk of cardiovascular disease. The combination of these two ingredients effectively improves cardiovascular health.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg once daily by mouth as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg once daily by mouth. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It should not be used in patients with a known allergy to this medication, during pregnancy or breastfeeding, or in patients with severe liver or kidney impairment. Patients with weakened liver or kidney function, elderly patients, and those with hyperkalemia should use this medication with caution, requiring regular blood tests and health evaluations. If symptoms such as muscle pain, weakness, dizziness, or indigestion occur, consult a physician immediately, and the medication may need to be discontinued in severe cases. This medication may interact with other drugs, so it is important to inform your doctor or pharmacist of any other medications you are taking. Particularly for patients being treated simultaneously for hypertension and hyperlipidemia, dose adjustments and monitoring of side effects are important. Caution is required as dizziness or drowsiness may occur when driving or operating machinery. It is not recommended for children, as safety and efficacy have not been established.
Increased ALT, Increased AST, Increased serum creatine phosphokinase (CPK), Dizziness, Itching, Indigestion, Oral sensory disturbances, Musculoskeletal stiffness, Acne, Nasopharyngitis, Increased serum potassium, Glycosuria, Dysuria, Rhinitis, Oral pharyngeal discomfort, Lung disease, Unspecified intestinal disorder, Benign gastrointestinal neoplasm, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory loss, Movement disorders, Atherosclerosis, Frequent urination, Tinnitus, Hearing loss, Halitosis, Fatty liver, Upper respiratory tract infection, Urinary tract infection, Sepsis, Anemia, Thrombocytopenia, Eosinophilia, Hypersensitivity, Anaphylactic reaction, Hyperkalemia, Hypoglycemia, Depression, Insomnia, Anxiety, Syncope, Visual disturbances, Dizziness, Bradycardia, Tachycardia, Hypotension, Orthostatic hypotension, Dyspnea, Abdominal pain, Diarrhea, Abdominal bloating, Vomiting, Abdominal discomfort, Dry mouth, Liver function abnormalities, Liver disorder, Increased sweating, Rash, Erythema, Angioedema, Drug rash, Toxic epidermal necrolysis, Eczema, Urticaria, Myalgia, Lumbar pain, Muscle cramps, Arthralgia, Limb pain, Tendon pain, Acute renal failure, Chest pain, Weakness, Influenza-like illness, Increased blood creatinine, Increased blood uric acid, Elevated liver enzymes, Increased blood CK, Decreased hemoglobin, Liver dysfunction, Jaundice, Anaphylactoid symptoms, Interstitial pneumonia, Rhabdomyolysis, Palpitations, Fatigue, Nausea, Ineffectiveness, Headache, Facial spasms, Sensory abnormality, Paralysis, Cough, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Anorexia, Edema, Decreased libido, Facial edema, Hair loss, Conjunctivitis, Tinnitus, Petechiae, Angioedema, Hypersensitivity reactions including angioedema, Diabetes, Headache, Constipation, Nausea, Pancreatitis, Rash, Urticaria, Myopathy, Weakness, Polyneuropathy, Amnesia, Peripheral neuropathy, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Increased transaminases, Stevens-Johnson syndrome, Drug reaction with eosinophilia and systemic symptoms, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Sexual dysfunction, Gynecomastia, Interstitial lung disease, Fatal and non-fatal liver failure, Cognitive impairment, Severe myasthenia gravis, Ocular myasthenia gravis, Myalgia, Joint pain, Increased CK, Numbness, Sensory abnormalities, Chest discomfort, Abdominal distension, Syncope, Systemic pain, Muscle cramps, Gout
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that is not affected by air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to safely preserve the medication's effectiveness.
Pale yellow oval film-coated tablets
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
IlYang Biopharm Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.